AP NEWS
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

CytoDyn to Present at Wall Street Reporter’s “NEXT SUPER STOCK Live” Conference on November 14, 2019

November 14, 2019 GMT

VANCOUVER, Washington, Nov. 13, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer will present a comprehensive overview of the Company’s clinical, regulatory and commercialization priorities at Wall Street Reporter’s “NEXT SUPER STOCK Live” Conference on Thursday, November 14, 2019 at 1:10 pm ET / 10:10 am PT and will be available online.

Date: Thursday, November 14, 2019 Time: 1:10 p.m. ET / 10:10 a.m. PT Access: https://www.wallstreetreporter.com/next-superstock-online-investor-conference/

The livestream presentation will be archived for 30 days and participants are encouraged to go to the above-referenced website 10 minutes prior to the start of the presentation. The conference sponsor provides corporate visibility services to CytoDyn for a fee.

CONTACTS: Investors:Nader Pourhassan, Ph.D.President & CEO npourhassan@cytodyn.com